Answers are grounded in this paper and cite their sources.
The discovery of induced pluripotent stem cells (iPSC) was met with optimism that this new technology would revolutionize how we model and treat human diseases. The last 20 years of research, however, has somewhat tempered the initial enthusiasm as the technology is often challenging to adopt for a given application. Here we outline a methodology for using iPSC in tissue modeling by combining the environment of a microphysiological system (MPS) platform, the vascularized micro organ (VMO), with more nuanced differentiation techniques to create microvessels using iPSC-derived endothelial cells (iEC) suitable for long-term in vitro tissue studies. We describe the impact of optimized differentiation conditions on iEC beyond selection tools usually sufficient for identifying functional primary EC and offer key metrics for the unique characterization and evaluation of the vasculogenic potential of these iEC. Instead of relying solely on expression of key EC identity genes such as CD31 and VWF to assume differentiation efficiency, we propose a novel screening panel to predict the functional capacity of iEC. In vasculogenic EC we consistently observed expression of eight genes ( TPM1 , IARS1 , SPARC , PTPN13 , NOTCH2 , TTC3 , CNN2 and CBX5 ) while low or absent expression of a further eight genes ( ID3 , CALCRL , WWTR1 , ERG , MYCT1 , DUSP6 , FZD4 and STAB1 ) clearly predicted poor vasculogenic potential. These innovations and robust characterization will help to identify iEC that can be used in the generation of novel vascularized disease platforms that capture patient genetic variability and/or replicate in situ gene expression of genetic disorders.
No takes yet. Share an insight, caveat, or question.
Trigt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: